The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015

Carregando...
Imagem de Miniatura
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
SILVEIRA, Mariangela F.
BUFFARINI, Romina
BERTOLDI, Andrea D.
SANTOS, Ina S.
BARROS, Aluisio J. D.
MENEZES, Ana Maria B.
GONCALVES, Helen
HORTA, Bernardo L.
BARROS, Fernando C.
Citação
VACCINE, v.38, n.3, p.482-488, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Vaccine hesitancy has been increasingly reported in Brazil. We describe secular trends and socioeconomic disparities from 1982 to 2015, using data from four population-based birth cohorts carried out in the city of Pelotas. Full immunization coverage (FIC) was defined as having received four basic vaccines (one dose of BCG and measles, and three doses of polio and DTP) scheduled for the first year of life. Information on income was collected through standardized questionnaires, and the slope index of inequality (SII) was calculated to express the difference in percent points between the rich and poor extremes of the income distribution. Full immunization coverage was 80.9% (95% CI 79.8%; 82.0%) in 1982, 97.2% (96.1%; 98.0%) in 1993, 87.8% (86.7%; 88.8%) in 2004 and 77.2% (75.8%; 78.4%) in 2015. In 1982 there was a strong social gradient with higher coverage among children from wealthy families (SII = 25.0, P < 0.001); by 2015, the pattern was inverted with higher coverage among poor children (SII = -6.0; P = 0.01). Vertical immunization programs in the 1980s and creation of the National Health Services in 1980 eliminated the social gradient that had been present up to the 1980s, to reach near universal coverage. The recent decline in coverage is likely associated with the growing complexity of the vaccination schedule and underfunding of the health sector. In addition, the faster decline observed among children from wealthy families is probably due to vaccine hesitancy.
Palavras-chave
Immunization coverage, Vaccination hesitancy, Economic status, Educational status, Socioeconomic factors, Public health, Cohort studies
Referências
  1. [Anonymous], 2018, 2018 ASS REP GLOB VA
  2. Ballalai Isabella, 2018, MEASLES BRAZIL UNWEL
  3. Barata RCB, 2000, REV PANAM SALUD PUBL, V8, P332, DOI 10.1590/S1020-49892000001000003
  4. Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
  5. Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
  6. Barros AJD, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001390
  7. Bedford H, 2000, BRIT MED J, V320, P240, DOI 10.1136/bmj.320.7229.240
  8. Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
  9. Bertoldi AD, 2019, INT J EPIDEMIOL, V48, pi4, DOI 10.1093/ije/dyy170
  10. Binyaruka P, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3270-z
  11. Yokokura AVCP, 2013, CAD SAUDE PUBLICA, V29, P522, DOI 10.1590/S0102-311X2013000300010
  12. Castro MC, 2019, LANCET, V394, P345, DOI 10.1016/S0140-6736(19)31243-7
  13. Centro de Vigirancia Epidemiologica. Govern do Estado de Sao Paulo, 2019, B EPIDEMIOLOGICO, V1
  14. Centro Estadual De VigilSncia em Saticle (CEVS), 2018, VIG DOEN IM 2017
  15. Couto MT, 2015, CIENC SAUDE COLETIVA, V20, P105, DOI 10.1590/1413-81232014201.21952013
  16. Branco FLCC, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0118-y
  17. Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008
  18. Ferreira VLD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311X00184317, 10.1590/0102-311x00184317]
  19. Goncalves H, 2019, INT J EPIDEMIOL, V48, pi80, DOI 10.1093/ije/dyy233
  20. Hallal PC, 2018, INT J EPIDEMIOL, V47, P1048, DOI 10.1093/ije/dyx219
  21. Hortal M, 2019, REV PANAM SALUD PUBL, V43, DOI 10.26633/RPSP.2019.54
  22. Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
  23. Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
  24. Luhm KR, 2011, REV SAUDE PUBL, V45, P90, DOI 10.1590/s0034-89102010005000054
  25. MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
  26. McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003
  27. Menezes AMB, 2019, INT J EPIDEMIOL, V48, pi54, DOI 10.1093/ije/dyy129
  28. Middleton E, 2003, BMJ-BRIT MED J, V326, P854, DOI 10.1136/bmj.326.7394.854
  29. Miko D, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060282
  30. Ministerio da mulher dfeddh, 2019, EST CRINC AD
  31. Ministerio da Sande, 2018, COORD GER DOENC TRAN
  32. Ministerio da Saude. Secretaria de Vigilancia em Satide, 2015, COB VAC BRAS PER 201
  33. Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
  34. Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
  35. Plotkin SA, 2008, VACCINES
  36. Santos IS, 2011, INT J EPIDEMIOL, V40, P1461, DOI 10.1093/ije/dyq130
  37. Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/s1518-8787.2018052001199, 10.11606/S1518-8787.2018052001199]
  38. Silva FD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311X00041717, 10.1590/0102-311x00041717]
  39. Suarez L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e3
  40. Tauil MD, 2017, EPIDEMIOL SERV SAUDE, V26, P835, DOI [10.5123/S1679-49742017000400014, 10.5123/s1679-49742017000400014]
  41. VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120
  42. Victora CG, 2008, INT J EPIDEMIOL, V37, P704, DOI 10.1093/ije/dym177
  43. VICTORA CG, 1991, REV SAUDE PUBL, V25, P218, DOI 10.1590/S0034-89101991000300009
  44. Victora CG, 2006, INT J EPIDEMIOL, V35, P237, DOI 10.1093/ije/dyi290
  45. Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0
  46. WHO, 2018, IMM COV
  47. Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430